Antibody Responses to NY-ESO-1 in Breast Cancer
Author Information
Author(s): Hamaï Ahmed, Duperrier-Amouriaux Karine, Pignon Pascale, Raimbaud Isabelle, Memeo Lorenzo, Colarossi Cristina, Canzonieri Vincenzo, Perin Tiziana, Classe Jean-Marc, Campone Mario, Jézéquel Pascal, Campion Loïc, Ayyoub Maha, Valmori Danila
Primary Institution: Institut National de la Santé et de la Recherche Médicale, Unité 892, CLCC René Gauducheau, Saint Herblain, France
Hypothesis
The presence of antibodies to NY-ESO-1 can identify a specific subtype of primary breast cancer that may benefit from immunotherapy.
Conclusion
The presence of antibodies to NY-ESO-1 identifies a subtype of hormone receptor-negative primary breast cancer with frequent ESO expression, which may be targeted for immunotherapy.
Supporting Evidence
- 1% of patients had detectable antibody responses to NY-ESO-1.
- 20% of hormone receptor-negative breast cancers expressed NY-ESO-1.
- Patients with antibodies had higher numbers of tumor-invaded lymph nodes.
Takeaway
Some breast cancer patients have special antibodies that can help doctors find the right treatment for them.
Methodology
The study assessed circulating antibodies to NY-ESO-1 in 1374 breast cancer patients using ELISA and correlated findings with tumor characteristics.
Potential Biases
Potential bias due to the selection of patients from a single center.
Limitations
The study only included patients from a single institution and may not represent all breast cancer patients.
Participant Demographics
Patients with primary breast cancer, including hormone receptor-negative and positive subtypes.
Statistical Information
P-Value
1%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website